2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

4:30PM-6:00PM: Abstract Number: 1880

Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience

Miscellaneous Rheumatic and Inflammatory Diseases I

4:30PM-6:00PM: Abstract Number: 1926

Cardiac Remodeling in Systemic Sclerosis: TGF-β/Fra2-Dependent Autophagy As a Novel Target for Heart Fibrosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 1922

Cell Type Specific Gene Expression Analysis of Early Systemic Sclerosis Skin Shows a Prominent Activation Pattern of Innate and Adaptive Immune System in the Prospective Registry for Early Systemic Sclerosis (PRESS) Cohort

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 1886

Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 1874

Development of an Ultrasonographic Enthesitis Score for Psoriatic Arthritis Patients

Imaging of Rheumatic Diseases I: Novel Imaging and Scoring Systems

4:30PM-6:00PM: Abstract Number: 1914

Discovery of a Novel CD8+ T Cell Population in Ankylosing Spondylitis Implicates Gut-Joint Trafficking in the Disease

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology

4:30PM-6:00PM: Abstract Number: 1900

Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects III: Obesity and Other Comorbidities

4:30PM-6:00PM: Abstract Number: 1888

Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 12 Months in Subgroups of Glucocorticoid-Treated Individuals

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 1869

Effects of Add-on Transcranial Direct Current Stimulation on Pain in Korean Patients with Fibromyalgia

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 1885

Epidemiology of Hospitalized Adult Onset Still’s Disease in United States

Miscellaneous Rheumatic and Inflammatory Diseases I

4:30PM-6:00PM: Abstract Number: 1910

ERAP1 Deficiency Implicates Long Peptides in Protection from HLA-B27-Induced Experimental Spondyloarthritis

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology

4:30PM-6:00PM: Abstract Number: 1873

Evaluating Pain Related Disability in Fibromyalgia: A Comparison of the Fibromyalgia Impact Questionnaire and the Polysymptomatic Distress Scale

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 1861

Evaluation of a Longstanding Telephone Peer Counseling Service on People with Systemic Lupus Erythematosus and Their Loved Ones

ARHP Education/Community Programs

4:30PM-6:00PM: Abstract Number: 1894

Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study

Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Autoinflammatory Diseases

4:30PM-6:00PM: Abstract Number: 1915

Gut-Derived TNF As Risk Factor for the Development of Sacroiliac Inflammation

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].